Why the study?
What is the rate of patent ductus arteriosus closure in premature infants using an adjustable indomethacin dosing strategy based on second-dose peak plasma levels?
Population
103 premature infants treated with indomethacin for a patent ductus arteriosus (PDA)
Design
Cohort
Authors
Loading...
May support individualized indomethacin dosing for PDA in preterm infants; leaves open efficacy versus fixed regimens in controlled trials.
What is the rate of patent ductus arteriosus closure in premature infants using an adjustable indomethacin dosing strategy based on second-dose peak plasma levels?
An adjustable indomethacin dosing strategy based on second-dose peak plasma levels achieved a 64% PDA closure rate in premature infants, though this is lower than rates seen with serial monitoring.
O’Donovan et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: